(Total Views: 74)
Posted On: 11/09/2017 10:59:59 AM
Post# of 124969
$AZN sales in China are booming—despite lackluster RoW results:
https://uk.reuters.com/article/uk-astrazeneca...KKBN1D91RR
Quote:
China revenue in the third quarter increased by 12 percent at AstraZeneca and the country now accounts for 15 percent of its global product sales - a far higher proportion than at other big pharma companies.
… straZeneca has had five new products recently added to the country’s National Reimbursement Drug List - Onglyza for diabetes, cancer drugs Iressa and Faslodex, heart medicine Brilinta and antipsychotic treatment Seroquel.
This could help many pharma companies get sales, because of this faster new drug approval>>>
http://thebricspost.com/china-set-to-hasten-p...gR7adNSzIV
https://uk.reuters.com/article/uk-astrazeneca...KKBN1D91RR
Quote:
China revenue in the third quarter increased by 12 percent at AstraZeneca and the country now accounts for 15 percent of its global product sales - a far higher proportion than at other big pharma companies.
… straZeneca has had five new products recently added to the country’s National Reimbursement Drug List - Onglyza for diabetes, cancer drugs Iressa and Faslodex, heart medicine Brilinta and antipsychotic treatment Seroquel.
This could help many pharma companies get sales, because of this faster new drug approval>>>
http://thebricspost.com/china-set-to-hasten-p...gR7adNSzIV
(0)
(0)Scroll down for more posts ▼
